Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06992999 · ClinicalTrials.gov registry record · Phase 1
Psilocybin for Treatment of OCD-2
A Phase 1 study, sponsored by Francisco A Moreno.
- Not yet
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT06992999 is a Phase 1 study that has not yet begun recruiting, run by Francisco A Moreno. The registered enrollment target is 20 participants.
The verdict
NCT06992999, a Phase 1 study, has not yet begun recruiting, sponsored by Francisco A Moreno.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Previous research indicates that psilocybin, a drug that changes activity in brain areas believed to be involved in obsessive-compulsive disorder (OCD), might improve treatment for, and improve lives of, people diagnosed with OCD. The investigators propose to study 20 patients with symptomatic OCD who are not taking mind altering medications or street drugs, to participate in a 12 week study. Participants will be assigned (by luck of the draw) to take low or high dose psilocybin in four dosing sessions separated by 3 weeks. Measurements for the severity of OCD, ability to function, perception of quality of life, safety and tolerability will be measured at baseline prior to drug administration, during the dosing periods, and at the end of study. Other measurements will include brain imaging via fMRI and brain tracing via electroencephalogram (EEG). The investigators believe that during medically supervised dosing sessions, both doses of psilocybin will be safe and well tolerated, and will reduce OCD symptoms. Because psilocybin is a potent drug and especially at the higher dose may induce altered states of consciousness, a thoughtfully implemented procedure for participant safety is in place. Information will be obtained to explore the effects of altered states of consciousness in the outcome of treatment and to find the mechanism of benefit.
Interventions
- DRUG Low Dose Psilocybin
- DRUG High Dose Psilocybin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-09-08 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06992999
The ClinicalTrials.gov registry entry for NCT06992999 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Francisco A Moreno, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Low Dose Psilocybin is the first listed.
NCT06992999 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06992999 about?
NCT06992999 is a clinical study titled "Psilocybin for Treatment of OCD-2". Previous research indicates that psilocybin, a drug that changes activity in brain areas believed to be involved in obsessive-compulsive disorder (OCD), might improve treatment for, and improve lives of, people diagnosed with OCD. The investigators propose to study 20 patients with symptomatic OCD w...
What is the current status of trial NCT06992999?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2026-09-08. Estimated completion is 2028-12.
What interventions are being tested in trial NCT06992999?
The interventions under investigation include: Low Dose Psilocybin (DRUG), High Dose Psilocybin (DRUG).
Who is sponsoring clinical trial NCT06992999?
This trial is sponsored by Francisco A Moreno, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.